The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 2, 2009, Pages 116-128

  Yu, Yong Feng ^a   Chen, Zhi Wei ^a   Li, Zi Ming ^a   Li, Zong Hai ^b   Lu, Shun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

angiogenesis; cetuximab; endostatin; lung neoplasms

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; TETRAZOLIUM; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 65549097685     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.03.001     Document Type: Article

References (35)

1. Folkman J. Tumor angiogenesis and tissue factor. Nat Med. 2 (1996) 167-168
2. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19 (1995) 183-232
3. Rusch V., Klimstra D., Venkatraman E., et al. Over expression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 3 (1997) 515-522
4. Fontanini G., De Laurentiis M., Vignati S., et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 4 (1998) 241-249
5. Fox S.B., Smith K., Hollyer J., et al. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res Treat. 29 (1994) 41-49
6. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 151 (1997) 1523-1530
7. Dinney C.P., Parker C., Dong Z., et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res. 3 (1997) 161-168
8. Rak J., and Kerbel R.S. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls. Cancer Metastasis Rev. 15 (1996) 231-236
9. Vanhoefer U. Molecular mechanisms and targeting of colorectal cancer. Semin Oncol. 32 Suppl 8 (2005) 7-10
10. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
11. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
12. Oh S.P., Kamagata Y., Muragaki Y., et al. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci U S A 91 (1994) 4229-4233
13. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
14. Claesson-Welsh L., Welsh M., Ito N., et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integr in-binding motif RGD. Proc Natl Acad Sci U S A 95 (1998) 5579-5583
15. Yamaguchi N., Anand-Apte B., Lee M., et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18 (1999) 4414-4423
16. Carmichael J., Mitchell J.B., DeGraff W.G., et al. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer. 57 (1988) 540-547
17. Yen L., You X.L., Moustafa A.E., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19 (2000) 3460-3469
18. Luca M., Huang S., Gershenwald J.E., et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 151 (1997) 1105-1113
19. Miller L.J., Kurtzman S.H., Wang Y., et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 18 (1998) 77-81
20. Herbst R.S., and Fidler I.J. Angiogenesis and lung cancer: Potential for therapy. Clin Cancer Res. 6 (2000) 4604-4606
21. Behrens C., Lin H.Y., Lee J.J., et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 14 (2008) 6014-6022
22. Westphal J.R., Van't Hullenaar R., Peek R., et al. Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer. 86 (2000) 768-776
23. Nissen L.J., Cao R., Hedlund E.M., et al. Angiogenic factors FGF2 and PDGF-BB synergistical-ly promote murine tumor neovascularization and metastasis. J Clin Invest. 117 (2007) 2766-2777
24. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res. 7 (2001) 2958-2970
25. Herbst R.S., and Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 29 Suppl 4 (2002) 27-36
26. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 3 (1997) 2703-2707
27. Mendelsohn J. Blockade of receptors for growth factors: An anticancer therapy-the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 6 (2000) 747-753
28. Perletti G., Concari P., Giardini R., et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 60 (2000) 1793-1796
29. Yokoyama Y., Green J.E., Sukhatme V.P., and Ramakrishnan S. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res. 60 (2000) 4362-4365
30. Dhanabal M., Ramchandran R., Volk R., et al. Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59 (1999) 189-197
31. Fontanini G., Faviana P., Lucchi M., et al. A high vascular count and over expression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer. 86 (2002) 558-563
32. Haraguchi M., Komuta K., Akashi A., et al. Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis. Oncol Rep. 9 (2002) 159-165
33. Li A., Dubey S., Varney M.L., et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 170 (2003) 3369-3376
34. Heidemann J., Ogawa H., Dwinell B., et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem. 278 (2003) 8508-8515
35. Chen J.J., Yao P.L., Yuan A., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 9 (2003) 729-737